UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/844,662	04/27/2001	Eva Raschke	8325-0012	9004
20855 ROBINS & PA	7590 08/28/200 STERNAK	EXAMINER		
1731 EMBARC	CADERO ROAD	KELLY, ROBERT M		
SUITE 230 PALO ALTO, 0	CA 94303		ART UNIT	PAPER NUMBER
			1633	
			MAIL DATE	DELIVERY MODE
			08/28/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
09/844,662	RASCHKE ET AL.		
Examiner	Art Unit		
ROBERT M. KELLY	1633		

F	ROBERT M. KELLY	1633	
The MAILING DATE of this communication appear	rs on the cover sheet with the o	correspondence addi	ess
THE REPLY FILED <u>15 August 2008</u> FAILS TO PLACE THIS APF	PLICATION IN CONDITION FOR	ALLOWANCE.	
1. The reply was filed after a final rejection, but prior to or on the application, applicant must timely file one of the following reapplication in condition for allowance; (2) a Notice of Appea for Continued Examination (RCE) in compliance with 37 CF periods:	ne same day as filing a Notice of a plies: (1) an amendment, affidavi I (with appeal fee) in compliance	Appeal. To avoid aban t, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request
a) The period for reply expires 3 months from the mailing date of b) The period for reply expires on: (1) the mailing date of this Adv no event, however, will the statutory period for reply expire late Examiner Note: If box 1 is checked, check either box (a) or (b) MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).	risory Action, or (2) the date set forther than SIX MONTHS from the mailing	g date of the final rejectio	n.
Extensions of time may be obtained under 37 CFR 1.136(a). The date on have been filed is the date for purposes of determining the period of exter under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the sho set forth in (b) above, if checked. Any reply received by the Office later th may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	nsion and the corresponding amount ortened statutory period for reply origi	of the fee. The appropria nally set in the final Office	te extension fee e action; or (2) as
 The Notice of Appeal was filed on A brief in complia filing the Notice of Appeal (37 CFR 41.37(a)), or any extens Notice of Appeal has been filed, any reply must be filed with AMENDMENTS 	ion thereof (37 CFR 41.37(e)), to	avoid dismissal of the	
3. The proposed amendment(s) filed after a final rejection, bu (a) They raise new issues that would require further cons (b) They raise the issue of new matter (see NOTE below) (c) They are not deemed to place the application in bette	ideration and/or search (see NO ⁻);	ΓE below);	
appeal; and/or (d) They present additional claims without canceling a co NOTE: (See 37 CFR 1.116 and 41.33(a)).			27.01.004)
4. ☐ The amendments are not in compliance with 37 CFR 1.121 5. ☐ Applicant's reply has overcome the following rejection(s): Section 1.121	See Continuation Sheet.		,
6. Newly proposed or amended claim(s) would be allow non-allowable claim(s).			
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is provided The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: Claim(s) withdrawn from consideration:		I be entered and an ex	planation of
AFFIDAVIT OR OTHER EVIDENCE			
 The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and swas not earlier presented. See 37 CFR 1.116(e). 			
9. The affidavit or other evidence filed after the date of filing a entered because the affidavit or other evidence failed to ove showing a good and sufficient reasons why it is necessary a	ercome <u>all</u> rejections under appea	al and/or appellant fails	to provide a
10. ☐ The affidavit or other evidence is entered. An explanation of REQUEST FOR RECONSIDERATION/OTHER	of the status of the claims after e	ntry is below or attache	ed.
 The request for reconsideration has been considered but of See Continuation Sheet. 	does NOT place the application in	condition for allowand	ce because:
12. ☐ Note the attached Information <i>Disclosure Statement</i>(s). (P13. ☐ Other:	TO/SB/08) Paper No(s)		
	/Robert M Kelly/		
	Examiner of Art Unit 163	33	

Continuation of 5. Applicant's reply has overcome the following rejection(s): Applicant's reply overcomes the double-patenting rejections, due to filing of TDs to each of the patents, except for the 6,919,204 and 6,824,978 patents. With regard to the filing of the declaration of Dr. Case on 7/9/08, the rejections of the claims under 102(e) by Patent Nos. 7,220,719; 7,163,824; 7,013,219; 6,979,539; 6,933,113; 8,824,978; 6,689,558; 6,607, 882; and 6,453,242 (to be clear, those patents which are declared by Dr. Case), are withdrawn as required by 35 USC 103(c).

Continuation of 11. does NOT place the application in condition for allowance because: With regard to the arguments against Applicant's non-withdrawn rejections under 102(e) and non-withdrawn rejections for double patenting, Applicant argues that the references do not necessarily and inevitably bind accessible regions of cellular chromatin, citing a references that histones bind to a region which the specific zinc finger utilized also binds, to thereby argue that the zinc fingers in the art may or may not bind to accessible regions, and the Examiner cannot argue that the region is actually "accessible", and therefore it is not proper anticipation. Such is again not persuasive. The specification teaches that the accessible region is defined as "a site in a chromosome, episome or other cellular structure comprising a nucleic acid, in which a target site is present in the nucleic acid can be bound by an exogenous molecule which recognizes the target site" (p. 11, paragraph 2). No distinction is made as to the type of exogenous molecule, hence, because the molecule itself binds, the molecule is one such exogenous molecule, as it is non-naturally occuring and it is therefore binding in an accessible region. Further, the cited references teach that the zinc fingers can bind to regions that are bound in chromatin structure, but that necessarily means it can also bind to Applicant's argued accessible region, as the absence of other proteins does even less to preclude the binding of the Zinc finger. To wit, the cited art does not say that Zinc fingers only bind to cellular chromatin, or inaccessible sites, but that in some cases it will bind to the cellular DNA whether or not it is bound up in cellular chromatin. Further, if the Examiner were to accept Applicant's arguments, Applicant's arguments actually demonstrate that their claims are not enabled, as the structure of the DNA segments which bind to the zinc finger proteins which will be accessible are not distinguished in any fashion from those which are not, and hence, the Artisan would have to find and test every possible probe of chromatin structure to see if any of them differentially bind to the region, then determine if the Zinc binds to the region, and such would necessarily be undue experimentation as it amounts to inventing the breadth of Applicant's invention for Applicant. However, the more reasonable interpretation is provided by Applicant's specificaiton, p. 11, paragraph 2, which states that if it binds, it binds to an acessible region, and hence, the Argument against enablement is not believed proper. Further, as Applicant's own argued description states that the accessible region is "generally one that that does not have a typical nucleosome structure" (p. 13, lines 11-12), which is broad, and does not make any requirements as to any structure in its broadest reasonable interpretation, and hence, is non-limiting as a definition, because it is "generally" one of these regions, but not always. Still further, if the Examiner were to ignore the reality of the definition and remove the word "generally" from the defintion, it would be in direct conflict with the other defintion, on page 11, paragraph (discussed above). On the other hand, as the definitions are coextensive, as the term "generally" removes the import of the definition, it appears the examiner's defintion is proper and the region, because it binds to the zinc finger, is actually an accessible region. Lastly, it is repeated from the previous after-final rejection, that, in addition to the enablement rejection above, it would appear that if the Examiner were to accept the arguments of Applicant, that they did not actually possess the invention claimed. To wit, p. 11, paragraph 2 also states that it is believed that the binding site is not packaged into normal chromatin, and that, even in light of their belief, they do not wish to be bound by any particular theory with regard to the binding site. As such, this is tantamount to an admission that these sites are not known as to whether or not they bind a site in accessible chromatin. Hence, the Artisan would not have been able to determine, according to Applicant's proposed defintion, that Applicant possessed the invention as claimed, or whether it was a wish list of options on the part of Applicant. However, again, the broader reasonable interpretation is made by the Examiner, in which, if the Zinc finger binds the DNA it must be an accessible region. The rejections as anticipated by Shin, et al., and/or by Stacey, et al., have not been argued by Applicant, however, it is argued for the pending appeal that these are properly anticipated. First, if the Examiner's intpretation of what an accessible region is proper, then it is necessarily anticipation in each case. Second, if Applicant's interpretation of their specification is accepted, there is simply no way to determine whether or not the zinc fingers of Zhang and/or Stacey are binding to an accessible site, as the office does not have the facilities to determine such. Because of that, it is up to Applicant to demonstrate that the site is not accessible under their interpretation of the specification. Hence, these rejections remain, and the withdrawn claims are not rejoined. Moreover, it is stressed that such rejoinder would require further consideration, and hence. Applicant would be required to file an RCE prior to consideration of such at this point anyway. The Examiner hopes that the responses have been sufficient to help Applicant clarify the issues for appeal, and looks forward to the filing of an appeal brief. Applicant is advised to carefully file their appeal brief to comply with 37 CFR 41.37(c)(1)(i)..(x). The board of appeals now has a staff to review the submission for compliance, and missing references and documents and a failure to fully comply with any of these provisions, will yield a non-compliant appeal brief notice. As a general form of guidance, the submission should be a set of stand-alone documents, not requiring the Judges to go back to the application file to determine or confirm anything.